Effective IMPD Writing. The Quality Part

Webinar: Effective IMPD Writing. The Quality Part

Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is required by competent authorities in EU.

The purpose of this webinar is to share the best practices in the preparation of IMPD in order to meet the expectations of competent authorities and to learn why effective CMC technical writing is crucial for the development of a high quality IMPD.

 

You will learn about:

1. Regulatory guidelines for the Investigational Medicinal Product Dossier

2. IMPD structure and content

3. Best practices for the preparation of IMPD

  • Best practices in IMPD Quality writing;
  • Writing style to produce accurate, concise, and clear technical text.

 

Starting Clinical Trials?

Make use of our expertise to smoothly prepare for clinical studies. Explore your options in a chat with one of our experts.

Who should attend? Professionals from the following fields:

  • Regulatory
  • R&D
  • QA/QC
  • Compliance
  • Product Development
  • Manufacturing

Duration: 40 min.

Speakers:

  • Head of the Central Functions for Regulatory Affairs, Ramunė Rūkienė;
  • Medical Writer, Eglė Deimantavičiūtė.
Ramunė Rūkienė, MSc

Ramunė Rūkienė, MSc

Head of Regulatory Affairs Central Operations

Other content that might interest you:

Building Health Literacy: The Value of Good Writing

Building Health Literacy: The Value of Good Writing

Scientists, doctors, and health authorities often use written communication to present their research, opinions, or guidelines to the patients. While the questions they approach may be complex, the language should not. In medical documents, misinterpreted information may endanger the health and life of a patient. Thus, the main goal in medical writing is to convey the message clearly and concisely to avoid misinterpretation.

read more
CMC: Down the road in effective IND/IMPD writing

CMC: Down the road in effective IND/IMPD writing

In the previous two articles, we have shared our experience on various aspects of effective IND/IMPD CMC writing, considering proper planning, assigning a dedicated CMC writing team, and having effective project management. In addition, we discussed technical writing particulars giving some key messages on document preparation. Now, we will discuss other important points. These are safety, data completeness, and geographical regions.

read more
Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information